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Polymyxins 
1947 from Paenibacillus polymyxa subsp. colistinus 
1959: FDA approved the prodrug (colistimethate, CMS) for parenteral use 
Phe Leu 
Narrow spectrum against Gram-negatives 
Most Enterobacteriaceae: E. coli, Enterobacter spp. 
Klebsiella spp., Citrobacter spp., Salmonella spp., and 
Shigella spp. 
Nonfermenters: A. baumannii, P. aeruginosa, Steno. 
maltophilia 
Naturally resistant: Proteus spp., M. morganii, 
Providencia spp., S. marcescens, Ps. mallei, B. cepacia, 
Brucella, Legionella, Campylobacter, V. cholerae 
Antibiotics tested Wildtype (WT) 
MDR 
Multidrug-
resistant 
XDR 
Extensively 
drug-
resistant 
PDR 
Pandrug-
resistant 
Ampicillin R R R R 
Amoxicillin-clav. S I/R R R 
Piperacillin-tazob. S I/R R R 
Cefoxitin S R R R 
Cephalotin S R R R 
Cefpodoxime S R R R 
Ceftriaxone S R R R 
Cefotaxime S R R R 
Ceftazidime S R R R 
Cefepime S S/R R R 
Aztreonam S R R R 
Imipenem S S R R 
Meropenem S S R R 
Gentamicin S S/R R R 
Tobramycin S S/R R R 
Amikacin S S R R 
Ciprofloxacin S R R R 
Doxycycline S R R R 
Trimethoprim/sulfa. S R R R 
Fosfomycin S S S/R R 
Tigecycline S S S/R R 
Colistin S S S/R R 
Klebsiella pneumoniae 
Aminoglycosides 
Beta-Lactams 
Quinolones 
Tetracyclines 
Penicillins 
Penicillins “protected” 
Cephalosporins Ig 
IIg 
IIIg 
IVg 
Miscellaneous 
Monobactams 
Carbapenems 
ESBLs 
Carbapenemases 
Frequently co-associated 
with ESBLs and 
carbapenemases 
“LAST OPTIONS” 

Giacobbe DR et al., CMI, 2015 
X2 for trend, P<0.001 
Six Italian hospitals, Jan 2010 – June 2014 
Monomicrobial BSI due to KPC-K. pneumoniae 
Colistin-S (control) vs. Colistin-R (case) 
Acquired Resistance: “Chromosomal First” 
CATIONIC GROUPS 
Naturally R species express 
arnBCADTEF operon and/or eptB gene  
A large panel of genes and operons are involved in qualitative modification of LPS 
(Poirel L et al., Clinical Microbiol Review, April 2017) 
Colistin-S 
Colistin-R 
ICU-patient – Italy (Bologna) 
• KKBO-1: KPC-Kp Colistin-S in blood 
• Colistin aerosolized, 25 days 
• Colistin i.v., 14 days 
• 30 days later 
KKBO-4: KPC-Kp Colistin-R in blood 
• Identical strains (=PFGE and ST258)  
Also confirmed in vitro 
- KKBO-1 on agar plates with colistin [8 mg/L] 
- Colistin-R mutants with 7 x 10-7 frequency 
- 60% had insertion of IS5-like 
- No fitness cost (same authors; AAC, 2015) 
47 Col-R KPC-Kp (mostly ST258) 
12 had mutated mgrB 
More IS inserted  
in mgrB 
IS in the promoter  
of mgrB 
Stop codon mgrB 
Italy and Greece, 2010-2012 
66 Col-R KPC-KP 
Mostly, ST258 and ST512 
mgrB status: 
• 41%: WT 
• 27%: Insertion of IS5-like at nt 75 
• 8%: g109a (G37S) 
• 5%: ΔmgrB locus? No amplification with 1F/R 
• 3%: Insertion of ISKpn14 at nt 124 
• Δ18/27 (frameshift and premature termination) 
• a7t (nonsense, premature termination) 
• Δg47 (frameshift and premature termination) 
• Δ109/119 (frameshift and premature termination) 
• Insertion of IS1F-like at nt 105 
• ΔmgrB (from -400 to +599) 
• t71a (L24H) 
• g83a (C28Y) 
Transcriptional analysis (qPCR) 
Col-S 
All affect pmrHFIJKLM operon, 
thus LPS  
Lancet Infect. Dis. 2015 November 18  
IncI2 
Highly conjugative with E.  coli 
(frequency of 101-103 cells per recipient) 
mcr- 1  encodes for a  
Phosphoethanolamine transferase enzyme 
Use of antibiotics in Food Producing Animals - SWITZERLAND 
Hinchliffe P et al., Scientific Reports, Jan 2017 
MCR-1 catalyzes transfer of PEA onto 
glucosamine saccharide of lipid A in the OM 
Less net negative 
charge (COL-R) 
5 membrane α-helices 
Periplasmic domain Catalytic domain 
Zinc metalloprotein 
Phenotypic tests 
(e.g., MIC with EDTA) 
Food animals Food Humans 
Skov and Monnet - Eurosurv. March, 2016 
Most strains were 
3GC-R and stored!  
Eurosurveillance July, 2016 
IncX4 
35 Kbp 
53 colistin-R E. coli of porcine origin 
• mcr-1 in 7 (13%) 
• mcr-2 in 11 (21%) 
52 colistin-R E. coli of 52 bovine origin 
• mcr-2 in 1 (2%) 
mcr-1 (1’626 bp) – mcr-2 (1’617 bp): 77% nt identity 
MCR-1 and MCR-2 proteins show 81% identity 
Identical to one found in Salmonella enterica 
(but mcr-negative) 
 
Very high conjugation frequency (1.7 x 10-3) 
Moraxella spp. 
China, 2015 
380 colistin-R E. coli from pig feces 
• mcr-3 in 7 (1.8%) 
200 colistin-R E. coli from chicken cloacae 
• No mcr-3 
45% and 47% nt identity with mcr-1 and mcr-2, respectively 
33% and 32% aa identity with MCR-1 and MCR-2, respectively 
 
MCR-3 showed 94-95% aa identity to proteins found in Aeromonas spp. 
IncHI2 
261 Kbp 
Very similar backbone 
compared to IncHI2 
plasmids carrying mcr-1 
Eurosurv. Aug, 2017 
ColE10 
8,749 bp 
IS5 flanked region: 
99% identity with  
Shew. frigidimarina  
MCR-4 has 82-99% aa identity with phosphoethanolamine 
transferases found in Shewanella spp. 
Conjugation only in 
presence of IncI2 
plasmid (helper) 
125 E. coli from piglets with diarrhea 
• 50 were colistin-R 
• 32 with mcr-1; 3 with mcr-2; 11 with mcr-4  
Strain R4278 
Plasmid integrated into 
chromosome; flanked by 
IS5 
34%, 35% and 49% aa identity with  
MCR-1, MCR-2, and MCR-3, respectively 
Colistin starts in animals 
Food 
producing 
animals 
Food chain Environment 
Wildlife Pets 
Companion Animals 
Hospitals Nursing homes 
Community LTCFs Travelers 
Workers 
at risk 
Slaughterhouses 
Vet 
Clinics 
Infection 
Colonization 
Contamination 
Zoo 
One Health Concept: mcr genes 
Real-time PCR: 24.8% 
Culture-based: 15.9%  
only mcr-1 
32 E. coli, 2 K. pneumoniae 
We need further details on 
the production process 
(chain of production) 
Enterobacteriaceae from river (n=105) and 
sewage (n=90) around Barcelona (2013) 
30 out of 90 from sewage were mcr-1-positive 
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28/29 (pulsotypes I, II, III) were ST1196 
Reported in carbapenemase producers  
from humans/dogs  
SYBRGreen-based real-time PCR 
 
Winter 2011 (Nov-Jan) vs. winter 2016 (Nov-Jan)  
P<0.05 
Evidence for the growing spread of mcr- 1  
E. coli: 13’526 strains 
• Colistin-R: n=59, 0.4%  
• of which mcr-1: n=19, 0.1%   
K. pneumoniae: 7’480 strains 
• Colistin-R: n=331, 4.4%  
• of which mcr-1: n=0, 0%   
Urine sample. Feb-March, 2016: 
2049 Enterobacteriaceae of which 1704 E. coli 
Only one E. coli mcr-1: prevalence 0.05% 
1144 stool samples. July-Oct, 2016: 
Colistin-R Enterobacteriaceae: prevalence 1.5-3.8% 
No mcr-1/-2 producers: prevalence 0.0% 
979 K. pneumoniae from 43 hospitals (2016): 
Only two mcr-1-positive: prevalence 0.2% 
Human infections/colonization 
with mcr-1-like producers 
44-y man hospitalized in Portugal 
VAP due to A. baumannii, P. aeruginosa, CP K. pneumoniae 
Successfully treated with colistin for 20 days 
After 2 months, ICU in France where  
E. coli WI1 and WI2 were found in stools  
COL 
0.25 
4 (mcr-1) 
E. coli WI2: contained two additional plasmids 
• IncX4, 33Kb: mcr- 1  
• IncL, 62Kb: blaOXA-48   
ST1288 
(identical) 
Wang Y et al., Lancet Infect Dis, Apr 2017 
Infections 
Colonization 
Sporadic cases (not screened before trip) 
Only 3GC-R strains tested for COL-R 
- Mulvey MR et al., LID, March 2016 
- Doumith M et al., JAC, April 2016 
- Arcilla MS et al., LID, Feb 2016 
What is the real prevalence of MCR-1 producers? 
ESBL/pAmpC/Carbapenemase 
producers with MCR-1 
MCR-1 producers 
(“Susceptible strains”) 
Plasmids carrying only mcr-1 (non-ESC-R) 
IncI2 
Liu YY et al., LID, 16:161, 2016 
IncP 
IncX4 
IncI1 
IncHI2 
1 week 
Before 
1 week 
After 3 months 12 months 
TRIP 
38 HVs living in Switzerland and traveling to India (Jan-Aug 2015) 
Questionnaire 
Stools 
6 months 
MICs Trek panels 
Molecular tests 
Supercarba 
BLSE agar 
ChromID ESBL 
Enrichment with 
cefuroxime 
Stools MALDI-TOF MS 
Before trip: 
- 3/38 (~8%) with CTX-Ms E. coli 
After trip: 
- 29/38 (~76%) with ESC-R-Enterobacteriaceae 
- 26/38 with CTX-Ms E. coli 
- 3/38 with DHA E. coli 
At 3 months: 
- 11/34 (~32%) with ESC-R-Enterobacteriaceae 
- 10/34 with CTX-Ms E. coli 
- 1/34 with CMY-2-like E. coli 
At 6 months: 
- 8/31 (~26%) with ESC-R-Enterobacteriaceae 
- 5/31 with CTX-Ms E. coli 
- 3/31 with cAmpC, CMY-2-like E. coli 
At 12 months: 
- 4/25 (~16%) with ESC-R-Enterobacteriaceae 
- All CTX-Ms 
All ESBL/pAmpC strains were:  
- polymyxins-S (MICs ≤1 mg/L) 
- PCR negative for mcr- 1  
   
“Standard screening” 
Enrichment  
with 
Colistin, COL  
(2 mg/L) 
Stools 
MacConkey 
ChromAgar Orientation 
PCR for mcr-1/2 
MICs Trek panels 
Further molecular tests 
• Phylogenetic-group 
• MLST 
• PBRT 
• Conjugation 
• Transformation 
• WGS/WPS 
MALDI-TOF MS 
E. coli 
Proteus spp. 
Morganella spp. 
Klebsiella spp. 
Enterobacter spp. 
Serratia spp. 
COL 
4 mg/L 
VAN 
8 mg/L 
CTX 
2 mg/L 
COL 
4 mg/L 
COL 
4 mg/L 
VAN 
8 mg/L 
Citrobacter spp. 
Pseudomonas spp. 
New screening 
strategy for  
COL-R strains 
Problem: species naturally R to COL 
M. morganii H. alvei E. coli E. coli + H. alvei 
S. aureus 
S. saprophyticus 
Enterococcus spp. 
Overall, no other species (only E.  coli) 
* 
Before After 12 months TRIP 
ID Age/Sex 
Trips 
last 
year 
Stools #1 
Days 
in 
India 
Stools #2 Stools #3 Stools #4 Stools #5 
18 52 F 
TUR 
ITA 
GER 
FRA 
POR 
- 9 - 
E.  coli non-ESC-R 
B2-ST141 
COL MIC = 6 mg/L 
PCR mcr-1 = neg 
- - 
19 53 F ITA - 20 - - - 
E.  coli non-ESC-R 
A/B1-ST5 
COL MIC = 6 mg/L 
PCR mcr- 1  = POS 
26 50 F 
ITA  
FRA 
E.  coli non-ESC-R 
D1-ST69 
COL MIC = 4 mg/L 
PCR mcr-1 = neg 
14 - - - - 
56 42 M 
ICE 
BEL 
UK 
- 9 - 
E. coli CTX-M 
New-ST 
COL MIC = 8 mg/L 
PCR mcr-1 = neg 
- - 
78 57 F 
SPA 
ITA 
AUT 
- 20 
E. coli CTX-M 
D2-New-ST 
COL MIC = 12 mg/L 
PCR mcr-1 = neg 
Drop out  Drop out Drop out 
86 53 F 
SPA 
POR 
ISR 
- 15 
E. coli DHA 
B1-ST3075 
COL MIC = 6 mg/L 
PCR mcr-1 = neg 
- - Drop out 
88 25 M 
NED 
ITA 
POL 
- 8 
E. coli CTX-M 
D1-New-ST 
COL MIC = 4 mg/L 
PCR mcr-1 = neg 
- - - 
100 57 F - - 14 
E.  coli non-ESC-R 
A1-ST10 
COL MIC = 12 mg/L 
PCR mcr- 1  = POS 
- - - 
COL-R 1/38 (2.6%) 
MCR-1 0/38 
COL-R 4/38 (10.5%) 
MCR-1 1/38 (2.6%) 
3 months 6 months 
New screening 
strategy for  
COL-R strains 
9 mcr- 1  E.  coli (3 humans; 6 meat) 
- 7 plasmid-mediated  
- 2 chromosomally located 
Prevalence of mcr-1 producers: 
- HIV+, 1% 
- Travelers, 5.2% 
- Chicken meat from Germany, 1.1% 
- Swiss chicken meat, 0% 
3GC-R 
3GC-R 
3GC-R 
Most with ISApI1  
Very similar or identical plasmids  
(highly stable!) 
 
Most are 
conjugative 
In blue from this study or Switzerland 
CMY-2-IncK2 plasmids 
represents a major attack in 
EU chicken production 
 
They are frequently carried by 
a hyperepidemic ST38 E.  coli 
clone transmitted to humans 
One chromosomal copy 
(in a ST38 E.  coli) 
Two chromosomal copies 
2,600 bp composite transposon (?) 
[Tn6330.2] 
Creation of two truncated forms 
No transposition events Transposition frequency (2.2 x 10-8) 
ISApl1 first identified in  
Actinobacillus pleuropneumoniae (Pasteurellaceae) 
Porcine necrotic pleuropneumonia 
Chew KL, JCM, Sep 2017 
Sensitivities for detecting mcr- 1-positive strains 
Performance in comparison to BMD 
Performance of simulated breakpoints 
CLSI, 2017: S ≤ 2 mg/L – R ≥ 2 mg/L (Ec, Kp, Ea, Ecl, Ro) 
EUCAST, 2017: S ≤ 2 mg/L – R > 2 mg/L 
Both recommend broth microdilution (BMD) 
Should we  
lower cutoff? 
76 Enterobacteriaceae  
(21 mcr-1) 
Not for disk! 
74 colistin-R Enterobacteriaceae  
(61 with mcr-1-like) 
Cation-adjusted MH broth 
(CLSI) 
A MIC reduction of at least 
8-fold dilution 
Jayol A. et al., J Clin Micro; 54:9, 2016 
Final results in 2-4 hrs 
Sens and Spec: 98% and 100%, respectively 
~10 Euro 
<2 hrs 
3.75 mg/L 
Carbohydrate metabolism 
Acid formation observed with pH indicator (phenol red) 
+ + 
Jayol A. et al. CMI, June 2017 
BMD, gold standard 
BD Phoenix automated system 
• 10 Very Major Errors (12%) 
Rapid Polymyxin NP test 
• 1 Very Major Error (1.2%) 
• 1 Major Error (1.2%) 
123 Enterobacteriaceae: 
83 were colistin-R 
Position of the ligation probes E. coli possessing  
mcr-1, blaCTX-M-1 and blaTEM-1 
E. coli possessing  
mcr-2 and blaTEM-1 
Highly accurate: both sens/spec: 100% 
50-85 Euro 
• Preparation (2-5 min) 
• No DNA extraction 
• Run time (<30 min) 
LAMP (Eazyplex SuperBug mcr- 1  kit) 
Loop-mediated isothermal Amplification 
Real-time fluorescent measurement 
Genie II platform 
~55 Euro 
104 Enterobacteriaceae: 
 - 67 mcr-1-positive 
 - 37 mcr-1-negative (including 9 colistin-R) 
 
Sensitivity and Specificity: both 100% 
TAT: < 20 minutes 
40 cycles with native stools 
Curve gDNA copies 
107  
106 
105 
104  
103 
102 
10  
NTC 
HIV+ 
E. coli 31349 
ST5 (IncX4) 
Traveler 
E. coli #100 
ST10 (IncHI2) 
Traveler 
E. coli #19 
ST5 (IncHI2) 
Positive 
37 cycles 
Positive 
34 cycles Negative 
100 mg stools eluted in 100 µL 
4 µL template; final reaction in 20 µL 
LOD: 10 copies / reaction 
30 cycles with the enrichment 
HIV+ 
E. coli 31349 
ST5 (IncX4) 
Traveler 
E. coli #100 
ST10 (IncHI2) 
Traveler 
E. coli #19 
ST5 (IncHI2) 
Positive 
 21 cycles 
Positive 
23 cycles 
Positive 
22 cycles 
Conclusions 
The prevalence of COL-R Enterobacteriaceae is increasing 
- Human hospital setting – especially K. pneumoniae 
- Chromosomal (mostly mgrB) 
- Animal/food/environment settings – especially E. coli 
- Plasmid-mediated mcr-1-like based 
Use of colistin 
mcr- 1-like are spreading rapidly  
- Plasmids highly stable and able to conjugate 
- Transposition of the ISAbI1 transposon 
- Species carrying mcr-like genes  
Detection of COL-R strains (incl. mcr- 1-like) presents issues 
- BMD is not routinely implemented (Etest and disks not adequate) 
- Automated systems have problems (VMEs) 
- Not many molecular systems have been developed 
- Expensive 
- Most of them not for clinical samples 
They can establish themselves 
into hyperepidemic MDR clones 
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